Medical Technology

@xconomy.com 3 years ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 3 years ago

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

@xconomy.com 4 years ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 4 years ago

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

@xconomy.com 4 years ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 4 years ago

Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More

@xconomy.com 4 years ago

Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug

@xconomy.com 4 years ago

Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?

@xconomy.com 5 years ago

Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues

@xconomy.com 5 years ago

To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango

@xconomy.com 5 years ago

TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push

@xconomy.com 5 years ago

Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More